公开(公告)号：US20210353611A1

公开(公告)日：2021-11-18

申请号：US17277441

申请日：2019-09-19

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran ELINAV ,  Eran SEGAL

IPC: A61K31/455 ,  A61K35/74 ,  A61P25/28

Abstract: A method of treating ALS in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount at least two metabolites.

公开(公告)号：US20200206283A1

公开(公告)日：2020-07-02

申请号：US16683332

申请日：2019-11-14

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran SEGAL ,  Eran ELINAV

IPC: A61K35/747 ,  A61K35/745 ,  A61K35/744 ,  A61K35/741 ,  A61P3/08

Abstract: A method of improving the glucose response in glucose tolerant and intolerant subjects is provided. The method comprises providing to the subject probiotic compositions, or agents which specifically reduce bacterial species.

公开(公告)号：US20190142875A1

公开(公告)日：2019-05-16

申请号：US16077751

申请日：2017-02-14

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Eran ELINAV ,  Eran SEGAL

IPC: A61K35/741 ,  A23L33/135 ,  A23L33/105 ,  A23L33/00 ,  A61K31/352 ,  C12Q1/689 ,  A61P3/04

Abstract: A method of analyzing the likelihood of weight regain in a subject who has reached a target weight by practicing a weight loss program is disclosed. The method comprises determining an amount or presence of at least one microbe and/or product thereof in the gut microbiome of the subject, wherein the amount of the at least one microbe is altered during a prior weight gain period of the subject to reach a level representative of an obese subject and further wherein the amount of the at least one microbe is retained at the level following the weight loss program, wherein the amount or presence of the at least one microbe or product thereof is predictive of weight regain.

公开(公告)号：US20160232311A1

公开(公告)日：2016-08-11

申请号：US15022643

申请日：2015-04-28

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Inventor： Eran SEGAL ,  Eran ELINAV

IPC: G06F19/00 ,  G06N99/00

CPC classification number: G16H50/20 ,  G06F19/3475 ,  G06N20/00 ,  G16H50/70 ,  Y02A90/26

Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.

Abstract translation: 公开了预测受试者对食物的反应的方法。 该方法包括：选择对象的反应未知的食物; 访问具有描述所述对象的数据的第一数据库，而不是所述对象对所选食物的响应; 访问具有与其他受试者对食物有关的数据的第二数据库，其他对象的反应包括至少一个其他受试者对所选食物的反应或与所述选定食物相似的食物; 以及基于所选择的食物分析数据库以估计受试者对所选食物的反应。

公开(公告)号：US20230330051A1

公开(公告)日：2023-10-19

申请号：US18027168

申请日：2021-09-20

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran ELINAV ,  Leviel FLUHR ,  Uria MOR

IPC: A61K31/201 ,  A61K31/198 ,  A61K31/465 ,  A61K45/06 ,  A23G4/12

CPC classification number: A61K31/201 ,  A61K31/198 ,  A61K31/465 ,  A61K45/06 ,  A23G4/12

Abstract: A method of treating obesity in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that specifically increases the amount of hexadecadienoate (16:2n6), N-acetylglycine, 1-palmitoyl-2-gamma-linolenoyl-GPC (16:0/18:3n6) and/or Hexanoylglycine; or an agent that decreases the amount of dimethylglycine (DMG) in the fecal metabolome of the subject. Agents suitable for same are also disclosed.

公开(公告)号：US20220362329A1

公开(公告)日：2022-11-17

申请号：US17875551

申请日：2022-07-28

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran ELINAV ,  Ido AMIT ,  Aleksandra Anna KOLODZIEJCZYK

IPC: A61K38/14 ,  A61P1/16 ,  A61K31/43 ,  A61K31/7036 ,  A61K31/4164

Abstract: Methods of treating acute liver disease acute liver diseases are provided. Accordingly, there is provided a method of treating acute liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of binding a component of a TLR-MYC signaling pathway selected from the group consisting of MYC, MYD88, TRIF and p38 and inhibiting expression and/or activity of the component.

公开(公告)号：US20220184148A1

公开(公告)日：2022-06-16

申请号：US17579638

申请日：2022-01-20

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran ELINAV ,  Eran SEGAL

IPC: A61K35/741 ,  A61B5/00 ,  C12Q1/02 ,  C12Q1/04 ,  G01N33/68 ,  C12Q1/6883

Abstract: A method of determining tolerance to an agent in a healthy subject is disclosed. The method comprises: (a) determining a signature of a microbiome in a sample of the healthy subject who has been subjected to the agent or condition; and (b) comparing the signature of the microbiome of the healthy subject to at least one reference signature of a pathological microbiome, wherein when the signature of the microbiome of the healthy subject is statistically significantly similar to the reference signature of the pathological microbiome, it is indicative that the healthy subject is intolerant to the agent.

公开(公告)号：US20210260139A1

公开(公告)日：2021-08-26

申请号：US17318009

申请日：2021-05-12

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran ELINAV ,  Eran SEGAL

IPC: A61K35/741 ,  C12Q1/689 ,  A23L33/00 ,  A23L33/105 ,  A61K31/352 ,  A61K35/74 ,  C12Q1/02 ,  A23L33/135 ,  A61P3/04

Abstract: A method of analyzing the likelihood of weight regain in a subject who has reached a target weight by practicing a weight loss program is disclosed. The method comprises determining an amount or presence of at least one microbe and/or product thereof in the gut microbiome of the subject, wherein the amount of the at least one microbe is altered during a prior weight gain period of the subject to reach a level representative of an obese subject and further wherein the amount of the at least one microbe is retained at the level following the weight loss program, wherein the amount or presence of the at least one microbe or product thereof is predictive of weight regain.

公开(公告)号：US20190267140A1

公开(公告)日：2019-08-29

申请号：US16412538

申请日：2019-05-15

Applicant: Yeda Research and Development Co. Ltd

Inventor： Eran SEGAL ,  Eran ELINAV

IPC: G16H50/20 ,  G06N20/00 ,  G16H50/70

Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.

公开(公告)号：US20180148770A1

公开(公告)日：2018-05-31

申请号：US15568818

申请日：2016-04-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran ELINAV ,  Eran SEGAL

IPC: C12Q1/689 ,  A61P1/00 ,  A61K31/417 ,  A61K31/132

CPC classification number: C12Q1/689 ,  A61K31/132 ,  A61K31/185 ,  A61K31/417 ,  A61P1/00 ,  G01N33/6893 ,  G01N2800/065 ,  G01N2800/52 ,  A61K2300/00

Abstract: A method of determining the therapeutic effect of an agent, such as a metabolite, comprising: (a) exposing a pathological microbiome to the agent; and (b) comparing the signature of the pathological microbiome following the exposing with a reference signature of a healthy microbiome, wherein when the signature of the microbiome is statistically significantly similar to the healthy microbiome reference signature, it is indicative that the agent has a therapeutic effect on the microbiome. The agent may be provided to a subject having a pathological microbiome once it has been classified as therapeutic.